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Abstract: Here, we describe the immunoglobulin and T cell receptor (Ig/TCR) molecular
rearrangements identified as a leukemic clone hallmark for minimal residual disease assessment
in relation to TP53 mutational status in 171 Ph-negative Acute Lymphoblastic Leukemia (ALL)
adult patients at diagnosis. The presence of a TP53 alterations, which represents a marker of poor
prognosis, was strictly correlated with an immature DH/JH rearrangement of the immunoglobulin
receptor (p < 0.0001). Furthermore, TP53-mutated patients were classified as pro-B ALL more
frequently than their wild-type counterpart (46% vs. 25%, p = 0.05). Although the reasons for the
co-presence of immature Ig rearrangements and TP53 mutation need to be clarified, this can suggest
that the alteration in TP53 is acquired at an early stage of B-cell maturation or even at the level of
pre-leukemic transformation.
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1. Introduction
Rearrangements of immunoglobulin (Ig) and T-cell receptors (TCR) genes are physiologic
mechanisms starting in the early stage of lymphopoiesis and following a hierarchical order in
which the DH-JH Ig rearrangement is one of the earliest events. The V, (D), J elements of these genes
are juxtaposed in different combinations to generate a diverse set of receptors capable to recognize
different antigens. [1,2] Therefore, Ig and TCR rearrangements represent fingerprint-like DNA regions
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of each distinct lymphoid cell and its descendants, making this peculiar characteristic a suitable
marker of clonality when cellular regulatory mechanisms fail. The identification of clonal Ig and TCR
rearrangements found clinical application in Minimal Residual Disease (MRD) detection, particularly in
Acute Lymphoblastic Leukemia (ALL). [3] Nowadays, it is established that MRD evaluation represents
the most important factor for predicting clinical outcome for ALL patients [4–6]. Despite the high
standardization level reached within European cooperative groups [7], clonality definition and MRD
assessment is time-consuming and is not feasible for all the patients, even when it is performed by
specialized laboratories. As a consequence, even if conventional risk factors defined at diagnosis still
maintain a crucial role, in recent years great efforts were made to identify new additional molecular
features useful not only for predicting outcome but also for the most appropriate treatment allocation.
The aberrations involving TP53 gene are detectable in about 10% of adult ALL patients at diagnosis and
represent a marker of poor prognosis [8–10]. Since the use of intensified treatments could potentially
overcome the dismal outcome usually reported in these patients [11], the identification of TP53
mutations at diagnosis is now mandatory.
Here, we present a study conducted on 171 adult Philadelphia negative-ALL patients in which
we analyzed the Ig/TCR molecular rearrangements identified as a leukemic clone hallmark in relation
to TP53 mutational status. All the patients were enrolled in the NILG-ALL 09/00 clinical trial, based on
the evaluation of MRD as a decisional tool for the post-consolidation program [5].
2. Patients and Methods
We analyzed the DNA samples obtained from the bone marrow or peripheral blood at diagnosis
containing at least 30% of blasts of 171 unselected ALL patients enrolled in the NILG-ALL 09/00
clinical trial (ClinicalTrials.gov identifier: NCT00358072). Our cohort of patients included 114 B
precursor ALL negative for t(9;22) or BCR/ABL1 transcripts and 57 T-lineage adult ALL. DNA was
extracted with commercially available kit (Gentra System, Germany) from mononuclear cells separated
on Ficoll gradient. DNA samples were studied to identify clonal rearrangements amplifying and
sequencing the VDJ/VJ regions of immunoglobulin heavy chain (IgH) or the kappa light chain (IgK),
and the T-cell receptor (TCR) gamma (G), delta (D) and beta (B) genes by conventional method [5]
or by an integrated NGS-based approach. Libraries for NGS were prepared by a custom NimbleGen
SeqCap Target Enrichment assay (Roche) targeting coding V, D and J genes in the Ig/TCR loci for the
identification of D-J and V-D-J rearrangements. Libraries were then sequenced on Illumina MiSeq
platform (2 × 300 bp). [12] Clone-specific oligonucleotides were designed based on the unique junction
region of each single rearrangement and used to perform MRD evaluation experiments by quantitative
PCR, as previously described. [5] The TP53 gene (exons 4–11) was sequenced by 454 Roche Sequencing
and data generated by this procedure were analyzed by GS Run Browser and GS Amplicon Variant
Analyzer software as previously described. [9] Based on the platform detection limits, we considered
only variants with a variant allele fraction (VAF) above 4%, which were checked in dbSNP, COSMIC
and IARC databases to investigate their biological significance. The TP53 mutations identified with
an allele burden >20% were also validated by PCR amplification and Sanger sequencing. Moreover,
TP53 copy number analysis was performed in 158 DNA samples by quantitative PCR method using
hTERT as reference gene. [9] Statistical tests used in the analysis are Chi-squared or Fisher-exact,
as appropriate.
3. Results and Discussion
The median age of the 171 ALL patients analyzed in this study was 34.6 (range, 15.6–64.8) and
male patients were 57%. Hepatosplenomegaly was present in 53% and CNS involvement in 6%.
The cytogenetic profile was normal/not adverse in 56%, not evaluable in 26% and adverse in 18%.
The complete remission achieved after induction chemotherapy was 91%. Within the TP53 exons
investigated, 16 mutations (single nucleotide variations and small insertion/deletion) were recognized
in 14 patients, accounting for the 8% of the cohort. In particular, the incidence of TP53 alteration
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was higher in B-ALL than in T-ALL (10% vs. 5%). We previously demonstrated that these molecular
aberrations were associated with the presence of one copy of TP53 gene and increasing age. Moreover,
all patients carrying a TP53 alteration reached complete remission (CR) after induction therapy but
13 out of 14 relapsed in a short time (within 15 months from CR achievement), showing that the
relapse rate was significantly higher in TP53 mutated than in wild-type subjects. By univariate
and multivariate analysis [9], the overall survival was strikingly affected by age, WBC at diagnosis
>30 × 109/L and CNS involvement. In addition, patients with a mutated TP53 gene showed a Leukemia
Free Survival (LFS) and Overall Survival (OS) which was dramatically shorter than for wild-type
patients, as previously described. [9] The identification of Ig/TCR clonal rearrangements for MRD probe
design by conventional PCR was unsuccessful in the majority of the TP53 mutated cases. Therefore, we
retrospectively applied an NGS approach [12] that allows the detection of a larger number of molecular
rearrangements. Thanks to this method, the identification of Ig/TCR clonal rearrangements was feasible
in all TP53-positive patients within the available diagnostic samples (13 out of 14). Interestingly, all the
B lineage-ALL patients mutated in the TP53 gene presented a DH/JH clonal rearrangement (10/10),
whereas no T-ALL (0/3) with an aberrant TP53 presented this type of rearrangement (Table 1).
The presence of a TP53 alteration was strictly correlated with an incomplete IgH rearrangement,
indeed, the 100% of B precursor ALL mutated for TP53 carried the DH/JH rearrangement, whereas
only the 36% of the wild-type B precursor-ALL showed the same types of rearrangement (p < 0.0001).
The DH/JH locus recombination is the first event that occurs in the IgH genetic recombination
mechanism, followed by the recombination of the VH genes with the rearranged DH-JH portion.
As previously described, the detection of an incomplete rearrangement denotes an early stage
of maturation of the leukemic cells, often associated with a less mature immunophenotype [13].
Conversely, the complete IgH V-D-J rearrangement was mostly associated with Bp-ALL wild type for
TP53 gene (p = 0.02).
Considering this, we investigated the surface antigen asset of our molecularly characterized B
cell derived-ALL cohort, and we found that all the TP53-mutated patients were defined as a B-I or
B-II ALL according to European Group for the Immunological Characterization of Leukemias (EGIL)
classification [14], which reflects the sequential stages of B-cell maturation. Furthermore, TP53-mutated
patients were classified as pro-B ALL more frequently than their wild-type counterpart (46% vs. 25%,
p = 0.05). Unfortunately, the number of T-ALL mutated for TP53 analyzed in this research was too
small to draw any conclusion about the co-occurrence TP53 mutation and DH/JH rearrangements,
which usually involves about 20% of the T-ALL [15]. In addition, 5 of the 10 TP53 mutated B-ALL
patients which presented a DH/JH clonal rearrangement were evaluable for MRD assessment in at least
two consecutive timepoints collected within the NILG protocol (Table 2). At least one of the samples
evaluated for each of these patients proved positive for leukemia persistence, suggesting a linkage
between TP53 mutation and MRD persistence. As previously specified, all these patients went toward
a clinical relapse.
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Table 1. Biological and molecular characteristics of TP53 mutated ALL NA = Not Available.
Patient ID Phenotype(EGIL) Cytogenetics Genetics
Risk
Class CR Relapse
CR
Duration
(Months)
Allo SCT (Outcome) Survival(Months) DH/JH
Sanger
Seq
Validation
BG_4205 B-common Normal Negative SR-B Y N 71.3+ N 71.3+ NA NA
BG_8345 B-common Normal Negative SR-B Y Y 6.6 N 17.2 DH3-22/JH6; DH1-26/JH4 Y; Y
BG_2873 pro-B Unknown Negative HR-B Y Y 13.8 N 17.4 DH6-6/JH6 Y
BG_11584 pro-B Unknown KMT2A-AFF1 HR-B Y Y 14.7 Y, with disease (dead due to persistent disease) 18.6 DH1-26/JH3 Y
BG_9445 B-common Hypodiploid Negative HR-B Y Y 10.2 Y, CR2 (Dead due to relapse) 12.9 DH2-2/JH6 Y
BG_5702 pro-B Hyperdiploid Negative HR-B Y Y 5.8 N 8.5 DH2-2/JH5 Y
BG_4254 pro-B Hyperdiploid Negative HR-B Y Y 5.0 N 16.4 DH3-9/JH6; DH6-6/JH5 Y; Y
BG_10112 pro-B Normal KMT2A-AFF1 HR-B Y Y 1.8 N 3.7 DH6-6/JH4; DH1-7/JH4 Y; Y
BG_11543 B-common Normal Negative SR-B Y Y 1.8 N 6.6 DH2-21/JH6 Y
BG_2097 B-common Complex Negative HR-B Y Y 3.7 N 7.3 DH4-23/JH2 Y
BG_6490 pro-B Hyperdiploid Negative HR-B Y Y 2.5 N 7.5 DH2-21/JH6; DH2-8/JH3 Y; Y
BG_10442 cortical-T Hyperdiploid Negative SR-T Y Y 4.6 Y, CR2 (Dead due to relapse) 11.1 NO DH/JH Y
BG_8142 cortical-T Hyperdiploid Negative SR-T Y Y 5.0 N 16.2 NO DH/JH Y
BG_8646 cortical-T Complex Negative HR-T Y Y 4.0 N 10.2 NO DH/JH N
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Table 2. MRD evaluation in the 5 TP53 mutated patients for whom a molecular probe was available.
Patient ID Phenotype(EGIL)
Available
Probe/s
Rearrangement
Used for MRD
Evaluation
Method for
Probe
Identification
MRD
Evaluation
at PRE4
MRD
Evaluation
at PRE6
MRD
Evaluation
at PRE8
BG_9445 B-common 1 DH2JH6A NGS - (*) - + (10−3)
BG_5702 pro-B 1 DH2JH5A NGS + (NQ) - + (NQ)
BG_11543 B-common 1 DD2DD3 Conventional + (10−3) + (10−3) + (10−3)
BG_2097 B-common 1 DH4JH2B NGS - +NQ + (10−1)
BG_6490 pro-B 2
DH2JH6A
NGS
+NQ - -
DH2JH3A +NQ - -
NA = Not Available, NQ = Not Quantifiable. Reproducible sensitivity was at least 10−4. * Inhibition of the tested
sample which can alter the MRD evaluation.
4. Conclusions
In conclusion, although in this study the number of B precursor ALL cases characterized by
both the presence of a mutation in the TP53 gene and an incomplete Ig rearrangement was relatively
small, these events were very strictly associated. This observation suggests that the presence of TP53
mutation should be investigated in all B-precursor ALL at diagnosis in parallel with the search for
specific incomplete DH/JH rearrangements for MRD evaluation. At this time, the reasons for the
co-presence of TP53 mutation and this type of incomplete DH/JH rearrangement remain to be clarified.
Nevertheless, this co-occurrence can suggest that the alteration of TP53 is acquired at the early stage of
the B-cell maturation, or even at the level of pre-leukemic transformation, as already described for
acute myeloblastic leukemia. [16] A comprehensive molecular characterization, now feasible by ad
hoc designed NGS panels, allows the identification of TP53 gene mutations and other prognostically
significant genes along with the Ig/TCR rearrangements for MRD evaluation. [12] This combined risk
stratification based on molecular genetics at diagnosis and MRD evaluation during treatment remains
feasible only at referral laboratories. Nonetheless, the clinical readout is so important that each ALL
patient should benefit from such a definition of the risk profile.
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